2-Bromo-6-methoxynaphthalene structure
|
Common Name | 2-Bromo-6-methoxynaphthalene | ||
|---|---|---|---|---|
| CAS Number | 5111-65-9 | Molecular Weight | 237.093 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 324.7±15.0 °C at 760 mmHg | |
| Molecular Formula | C11H9BrO | Melting Point | 106-109 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 134.7±6.4 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of 2-Bromo-6-methoxynaphthalene2-Bromo-6-methoxynaphthalene is an active intermediate in the production of anti-inflammatory agents like Naproxen and Nabumetone by Heck reaction. 2-Bromo-6-methoxynaphthalene has potential anti-inflammatory properties and Tyrosine-protein inhibitor properties. 2-Bromo-6-methoxynaphthalene can be used for the research of cancer[1]. |
| Name | 2-Bromo-6-methoxynaphthalene |
|---|---|
| Synonym | More Synonyms |
| Description | 2-Bromo-6-methoxynaphthalene is an active intermediate in the production of anti-inflammatory agents like Naproxen and Nabumetone by Heck reaction. 2-Bromo-6-methoxynaphthalene has potential anti-inflammatory properties and Tyrosine-protein inhibitor properties. 2-Bromo-6-methoxynaphthalene can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | 2-Bromo-6-methoxynaphthalene (2BMN) has anti-inflammatory properties in the molecular docking outcomes[1]. 2-Bromo-6-methoxynaphthalene has low interaction energy and inhibition constant for 6QDZ and 2Z7S[1]. |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 324.7±15.0 °C at 760 mmHg |
| Melting Point | 106-109 °C(lit.) |
| Molecular Formula | C11H9BrO |
| Molecular Weight | 237.093 |
| Flash Point | 134.7±6.4 °C |
| Exact Mass | 235.983673 |
| PSA | 9.23000 |
| LogP | 4.14 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.633 |
| InChIKey | AYFJBMBVXWNYLT-UHFFFAOYSA-N |
| SMILES | COc1ccc2cc(Br)ccc2c1 |
| Storage condition | Room temperature. |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi:Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36-S37/39 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2909309090 |
| Precursor 10 | |
|---|---|
| DownStream 10 | |
| HS Code | 2909309090 |
|---|---|
| Summary | 2909309090 other aromatic ethers and their halogenated, sulphonated, nitrated or nitrosated derivatives VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:5.5% General tariff:30.0% |
|
Preparation of Au–Ag–Pd trimetallic nanoparticles and their application as catalysts.
J. Mater. Chem. 13(5) , 978-980, (2003)
|
|
|
Preparation of Au–Ag–Pd trimetallic nanoparticles and their application as catalysts. Tsai SH, et al.
J. Mater. Sci. 13(5) , 978-980, (2003)
|
|
Name: AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of...
Source: The Scripps Research Institute Molecular Screening Center
Target: N/A
External Id: ULK1_INH_LUMI_1536_1X%INH PRUN
|
|
Name: insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen
Source: 846
Target: N/A
External Id: 5mMGluc_INS1E_InsulinRelease_40mMGluc_SP
|
|
Name: Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) small molecule antagonists: lu...
Source: NCGC
External Id: CYP3A4437
|
|
Name: Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) small molecule antagonists: lu...
Source: NCGC
External Id: CYP2D6395
|
|
Name: GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen
Source: 846
Target: N/A
External Id: GSK3b_inh_pretreated_Viability_ATP_HCT116_SP
|
|
Name: Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) small molecule antagonists: lu...
Source: NCGC
External Id: CYP2C9536
|
|
Name: GLP1 secretion from NCI-H716 cells-screen
Source: 846
Target: N/A
External Id: hNCI-H716_GLP1_Secretion_SP
|
|
Name: VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen
Source: 846
Target: N/A
External Id: VEGF_ADSC_ECFC_Angio_CD31_TubeArea_SP
|
|
Name: SW480 viability from Cell TiterGlo-screen
Source: 846
Target: N/A
External Id: Basal_Viability_ATP_SW480_SP
|
|
Name: HCT116 viability from Cell TiterGlo-screen
Source: 846
Target: N/A
External Id: Basal_Viability_ATP_HCT116_SP
|
| EINECS 225-837-0 |
| 2-bromonaroline |
| 6-Bromo-2-naphthyl methyl ether |
| 2-Bromo-6-methoxynaphthalene |
| 6-Methoxy-2-bromonaphthalene |
| MFCD00004062 |
| 6-bromonaphthalen-2-yl methyl ether |
| 2-BROMO-6-METHOXY-4-PYRIDINECARBOXYLIC ACID |
| 6-methoxy-2-naphthyl bromide |
| 4-PYRIDINECARBOXYLIC ACID,2-BROMO-6-METHOXY |
| 2-bromo-6-methoxy naphthalene |
| 2-Bromo-6-methoxyisonicotinic acid |
| 2-methoxy-6-bromo-naphthalene |
| 2-bromo-6-methoxyisonicotinate |